Evommune signs $1.1bn licence deal with Hinova for EVO570
Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares. Hinova is eligible to receive the remainder of the deal
Evommune will pay $30m upfront, consisting of $20m in cash and $10m in pre-funded warrants for common shares. Hinova is eligible to receive the remainder of the deal
The partnership will initially apply blood-based circular RNA profiling to PharmatrophiX’s LM11A-31 in Alzheimer’s, with potential expansion across its neurodegeneration pipeline. LM11A-31 is the company’s first-in-class small molecule
The pharmaceutical companies did not disclose the financial terms of the deal. Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated
The submission has been granted Priority Review, setting a target action date of 1 May 2027 under the Prescription Drug User Fee Act (PDUFA). The regulator also indicated
Set across a 6.5-acre site, the facility functions as the company’s sole distribution centre in the US. A workforce of 45 members handles administration, quality control, and general
The privately held clinical-stage biotechnology company will also use the capital to progress its broader research pipeline in autoimmune disorders, immunology, neurology, and oncology. Juvia Group and Lightspeed
Under the deal, Rumi Therapeutics will develop the therapy, renaming it RTX-7340. Enthorin Therapeutics will receive an upfront sum, an option exercise fee, and milestone payments. The company
The initiative will support the acquisition and clinical advancement of ten to 15 drug programmes over the next three to five years. The company plans to source Phase
The regulatory status specifically includes rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), the indication for which the candidate is presently being evaluated. Orphan status is granted to support the
Concurrently, the National Institute for Health and Care Excellence (NICE) has published Technology Appraisal guidance recommending funding for the National Health Service (NHS) for adult patients with genetically